There is an unmet need to identify novel treatments for patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL). The study by Bi and colleagues explores the clinical significance and therapeutic implications of the oncogene c-MYC (MYC) in ENKTL. They demonstrate that MYC has prognostic significance in ENKTL and also show that palbociclib, a CDK4 inhibitor, selectively inhibits malignant NK cells with MYC overexpression.

In chronic myeloid leukemia, the identification of early molecular predictors of stable, treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation is challenging. Saugues and colleagues used data from a real-world cohort of 408 patients to compare the value of the EUTOS long-term survival (ELTS) score, BCR:ABL1 halving time, and residual disease at 3 and 6 months in predicting molecular response, achievement of TKI discontinuation criteria, and TFR maintenance. The study shows that these are excellent as markers of TKI efficacy and for identifying best responders, but they do not predict achievement of criteria for TKI discontinuation criteria or TFR maintenance.